← Eichor
Study identifier: NCT04895956 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Intra-sheath vs Extra-sheath Injection for De Quervain's Tenosynovitis

Condition: De Quervain Tenosynovitis  ·  Sponsor: University of California, Davis

PhasePhase 4
Planned participants80
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The aim of the study is to determine whether or not extra-sheath steroid injections are inferior to intra-sheath steroid injections in the treatment of DeQuervain's Tenosynovitis. Patients will be randomized to either the intra-sheath group or the extra-sheath group and their pre-injection level of pain will be assessed using the visual analog scale. Appropriate injections will then be administered by 1 of 3 UC Davis hand surgeons. Six weeks post injection the patients will be reassessed using the visual analog scale and their score at 6 weeks will be compared to their pre-injection score.

This description comes directly from the study's public registry record.

Talk to the study team

Julia Martin, MS  ·  916-7348175  ·  jyhmartin@ucdavis.edu

Christopher O Bayne, MD  ·  (916) 734-2700  ·  cbayne@ucdavis.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UC Davis Health, Department of OrthopaedicsSacramento, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04895956